468 reports of this reaction
2.5% of all POLATUZUMAB VEDOTIN reports
#7 most reported adverse reaction
FEBRILE NEUTROPENIA is the #7 most commonly reported adverse reaction for POLATUZUMAB VEDOTIN, manufactured by Genentech, Inc.. There are 468 FDA adverse event reports linking POLATUZUMAB VEDOTIN to FEBRILE NEUTROPENIA. This represents approximately 2.5% of all 19,009 adverse event reports for this drug.
Patients taking POLATUZUMAB VEDOTIN who experience febrile neutropenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FEBRILE NEUTROPENIA is a less commonly reported adverse event for POLATUZUMAB VEDOTIN, but still significant enough to appear in the safety profile.
In addition to febrile neutropenia, the following adverse reactions have been reported for POLATUZUMAB VEDOTIN:
The following drugs have also been linked to febrile neutropenia in FDA adverse event reports:
FEBRILE NEUTROPENIA has been reported as an adverse event in 468 FDA reports for POLATUZUMAB VEDOTIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
FEBRILE NEUTROPENIA accounts for approximately 2.5% of all adverse event reports for POLATUZUMAB VEDOTIN, making it a notable side effect.
If you experience febrile neutropenia while taking POLATUZUMAB VEDOTIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.